High Throughput use of the Haemagglutination Inhibition Assay During Phase 3 Clinical Trials Using Large Virus Panels
Authors: Daryl Borley, Marianne Jaquet, Andrew Catchpole, Rob Lambkin-Williams, Lynne Batty, Peter Sargent, Nicolas Noulin.
hVIVO has for many years carried out the Haemagglutination Assay (HAI) at a high rate of throughput for clients. This assay, based on the World Health Organisation standardised assay is fully validated to FDA and ICH guidelines and many procedures have been introduced to improve the quality and reduce the variability of this assay. This includes several inter-laboratory comparative studies. The poster displayed here highlights some of these procedural changes and results of some of these interlab comparisons, along with data on the performance of the HAI assay at hVIVO and some examples of where the assay has been used in a high throughput fashion.
Fill out the form below to download the hVIVO poster presentation as made at ‘Influenza Vaccines for the World.’